PF-Atlas › Clinical Trials › NCT01621867

Repeated Application of Gene Therapy in CF Patients

pGM169/GL67A · Phase 2

Registry ID

NCT01621867

Phase

Phase 2

Status

Completed

Drug / intervention

pGM169/GL67A

Sponsor

Imperial College London

Start

2012-05

Enrollment

130

Locations

About this trial

Cystic fibrosis is a genetic condition where epithelial cells, including from the respiratory tract, have an abnormal function of a surface protein, the cystic fibrosis transmembrane conductance regulator (CFTR) protein resulting from abnormal gene expression. The trial will assess the clinical efficacy, safety \& tolerability and gene expression following repeated nebulised doses of a gene product coding for a normal CFTR protein, with the primary outcome of the trial assessing lung function.

View NCT01621867 on ClinicalTrials.gov →

Explore related

All pGM169/GL67A trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT01621867 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.